Humira (Adalimumab) for Hidradenitis Suppurativa gets positive opinion in Europe

Biopharmaceutical firm AbbVie’s Humira (adalimumab) has received positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to treat adults with moderate to severe hidradenitis suppurativa.

This positive opinion is based on the results of two Phase 3 studies (PIONEER I and PIONEER II). Patients treated with Humira (adalimumab) 40 mg weekly beginning at week 4 following a 160 mg dose at week 0 and an 80 mg dose at week 2, showed a significantly greater response at week 12 versus those on placebo.

If the European Commission grants approval, Humira (adalimumab) will become the first medication approved for hidradenitis suppurativa in all 28 member states of the European Union, as well as in Iceland, Norway and Lichtenstein.

1 Comment

  1. V Hill

    I’m so pleased to hear that the study of My disease has shown some benefits! Now for talking my Doctor into letting me try this!


Leave a Comment

Your email address will not be published. Required fields are marked *